2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.
2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.
Partners Sam Glick and Sven-Olaf Vathje write in Harvard Business Review on how countries around the world can learn from a broken American healthcare system.
What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.
As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.
How a “sticky” consumer experience could help control the drain of high-cost chronic disease drugs.
Trendspotting in unpredictable times. This infographic highlights five predictions for 2017.
Even amidst the uncertainty of repeal and replace, we see some meaningful trends taking shape. Read our predictions for 2017.
The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.
An insurance start-up, a venerable health system, and a new kind of payer-provider partnership.
Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.